BRCA1/2 Variants Associated With More Cancers Than Previously Thought
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
Most US women undergoing BRCA genetic testing do not receive genetic counseling despite multiple guidelines.
Although a broad BRCA-1/2 genetic testing program has been suggested for all US women, it is not recommended due to cost and lack of benefit.
Multigene testing for hereditary breast and/or ovarian cancer (HBOC) identifies more mutations that are likely to change clinical management.
The risk of breast and ovarian cancer varies with the type and location of BRCA1/2 mutations.
Use of localized correlated spectroscopy (COSY) shows significant changes in women with BRCA1 and BRCA2 mutations.
Carboplatin is associated with better outcomes than docetaxel in individuals with BRCA1/2 mutation-harboring breast cancer.
Reduction in BRCA mutation distress in breast cancer patients, unmet information needs with telephone-based, peer-support program.
Olaparib may be effective for the treatment of numerous advanced cancers caused by BRCA1 and BRCA2 mutations.
Celebrity story helped double rates of genetic testing in following six months at one cancer center.